Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040029/S021

Euclid Orthokeratology (oprifocon A) Contact Lenses for Overnight Wear, Euclid Orthokeratology (tisilfocon A) Contact Le

Euclid Vision Corporation · Decision date Mar 6, 2026

FDA DECISIONP040029/S021

What did the FDA approve?

FDA records P040029/S021 as a supplement to PMA P040029, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Mar 6, 2026.

FDA approval order statement

approval for toric periphery orthokeratology contact lens
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Ophthalmic
Decision date
Mar 6, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P040029/S021
Regulatory pathway
PMA supplement
Product code
NUU
Decision code
APPR
Decision date
Mar 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lens, contact, orthokeratology, overnight.

Product code
NUU
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P040029/S021 received

    Application receipt date recorded by FDA.

  2. P040029/S021 · FDA decision

    Normal 180 Day Track

  3. P040029/S025 · Related supplement

    Euclid Orthokeratology (oprifocon A) Contact Lenses for Overnight Wear and Euclid Orthokeratology (tisilfocon A) Contact

  4. P040029/S026 · Related supplement

    Euclid Orthokeratology (oprifocon A) Contact Lenses for Overnight Wear and Euclid Orthokeratology (tisilfocon A) Contact

Timeline entries are records held by MedtechLedger for P040029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040029

Explore the linked device profile

Other records with product code NUU

Product / regulatory recordCompanyPathwayDecision dateSource
Tianjin MasterVision Technology Co., Ltd.PMA approvalAug 5, 2026FDA
Contamac, Ltd.PMA approvalFeb 10, 2026FDA
Bausch & LombPMA supplementDec 16, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Euclid Vision Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
45472 Holiday Dr., Suite 7, Sterling, VA, 20166

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records